Cambridge, Massachusetts-based biotech Regor Therapeutics Group has agreed to sell its portfolio of CDK inhibitors for the treatment of breast cancer to Roche's Genentech for an upfront cash payment of $850 million, the companies announced today.'Genentech is well-positioned to bring these novel therapeutics to their full potential to benefit patients with breast cancer around the world,' Xiayang Qiu, founder and CEO of Regor, said in a statement.

总部位于马萨诸塞州剑桥的生物技术Regor Therapeutics Group已同意将其用于治疗乳腺癌的CDK抑制剂组合出售给罗氏基因泰克（Roche's Genentech），预付现金8.5亿美元，两家公司今天宣布Regor创始人兼首席执行官邱夏阳（Xiayang Qiu）在一份声明中表示，基因泰克（Genentech）处于有利地位，可以充分发挥这些新型疗法的潜力，使世界各地的乳腺癌患者受益。

' We are proud of the strong data we have generated to date. We look forward to bringing more innovative therapies to patients around the world.'The upfront payment could be supplemented with additional cash payments if certain 'development, regulatory, and commercial milestones' are met. The company did not disclose the milestones or the value of those payments.Under the terms of the deal, Genentech will take over clinical development, manufacturing, and commercialisation while Regor continues to manage ongoing phase 1 trials.Regor's primary product in breast cancer is RGT-419B and, if it pans out it will be the only CDK4 inhibitor in refractory ER+/HER2- breast cancer with single agent efficacy.

“我们对迄今为止生成的强大数据感到自豪。我们期待着为世界各地的患者带来更多创新疗法。”如果满足某些“发展、监管和商业里程碑”，则可以通过额外的现金支付来补充预付款。该公司没有透露这些付款的里程碑或价值。根据协议条款，基因泰克将接管临床开发、制造和商业化，而Regor将继续管理正在进行的第一阶段试验。Regor在乳腺癌中的主要产品是RGT-419B，如果它成功，它将是难治性ER+/HER2乳腺癌中唯一具有单药疗效的CDK4抑制剂。

Regor announced the results from a Phase1A dose escalation study last December. In a study of 12 patients, it was shown to be safe and well tolerated as well as showing promising signs of monotherapy efficacy.The company, which leverages a proprietary computer-accelerated drug discovery platform it calls CARD, has assets in metabolic disease and autoimmune as well as oncology.

Regor于去年12月宣布了第1A阶段剂量递增研究的结果。在一项针对12名患者的研究中，它被证明是安全且耐受性良好的，并且显示出单药治疗有效的有希望的迹象。该公司利用其称为CARD的专有计算机加速药物发现平台，在代谢疾病、自身免疫以及肿瘤学方面拥有资产。

Those assets, including some GLP-1s, are not included in the deal.This is not the first big pharma deal for Regor; in 2021 the company entered into a strategic research collaboration with Eli Lilly around its metabolic pipeline. That deal included a $50 million.

。这不是Regor的第一笔大型制药交易；2021年，该公司与礼来公司就其代谢管道进行了战略研究合作。这笔交易包括5000万澳元。